Back to search

Article

Synergistic Effect of Epigenetic Modulator Decitabine and Metformin in the Battle Against Gastric Cancer: A Potential Therapeutic Strategy 

2025-09-11

Abstract excerpt

<title>Abstract</title> <p> The 5-year global survival rate of patients with gastric cancer (GC) is approximately 20%; however, 74% of these patients survived for up to 1 year with effective therapy. The anticancer effects of metformin, an antidiabetic agent, and 5-Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), a DNA methyltransferase inhibitor that leads to malignant cell differentiation and apoptosis, have been...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a1f889c3-8b16-52a2-beee-78ec8adbfc70
DOI
10.21203/rs.3.rs-7382082/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Synergistic Effect of Epigenetic Modulator Decitabine and Metformin in the Battle Against Gastric Cancer: A Potential Therapeutic StrategyDOI 10.21203/rs.3.rs-7382082/v1
Select a neighboring publication to make it the new centre.